Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Data will be shared in two oral presentations, a poster and two online abstractsHighlights include a potential novel, ...

Specifically, new analyses show pelareorep induces a pro-inflammatory tumor microenvironment (TME) and activates both innate ...

MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase ...

Planning a cruise vacation but are unsure which NCL ship to travel on? This Norwegian Aqua vs Norwegian Prima guide breaks ...

Presentations will be available on the Alterity Therapeutics website here.

At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First Quarter Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation there ...

Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...

PDS Biotechnology Corporation (NASDAQ: PDSB) Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation ...

The U.S. Food and Drug Administration (FDA) granted GNSC-001 Fast Track designation in the fourth quarter of 2024. Genascence recently completed a successful meeting with the FDA on the design of ...

Neighborhood association leaders in Colorado Springs, many of them members of the Historic Neighborhoods Partnership (HNP), ...